Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

New AHA/ACC Performance and Quality Metrics for Coronary Revascularization

Michael O'Riordan

July 28, 2023

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Daily News

AHA Scientific Statement Addresses Health Disparities in PAD

L.A. McKeown

June 23, 2023

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Daily News

Diabetes Influences Relative Effects of Ticagrelor, Prasugrel in ACS: ISAR-REACT 5

Todd Neale

October 09, 2020

News Conference News ACC 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Yael L. Maxwell

March 30, 2020

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes

Michael O'Riordan

April 17, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

News Daily News

冠脉内阿昔单抗显示对糖尿病 STEMI 患者有优势

L.A. McKeown

August 11, 2016

News Daily News

Vorapaxar可对先前患过心梗的糖尿病患者起到有效的二级预防作用

L.A. McKeown

February 22, 2015

News Daily News

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

L.A. McKeown

February 22, 2015

News Daily News

Mejor Respuesta al Clopidogrel a Mayores Niveles de Tabaquismo

Jason Kahn

March 21, 2012

News Daily News

Better Clopidogrel Response Seen with Increased Smoking Levels

Jason Kahn

March 21, 2012

News Daily News

Prasugrel Inhibits Platelet Function Better Than High-Dose Clopidogrel in Diabetics

Jason Kahn

January 26, 2011

Advertisement

New AHA/ACC Performance and Quality Metrics for Coronary Revascularization

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

AHA Scientific Statement Addresses Health Disparities in PAD

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Diabetes Influences Relative Effects of Ticagrelor, Prasugrel in ACS: ISAR-REACT 5

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

冠脉内阿昔单抗显示对糖尿病 STEMI 患者有优势

Vorapaxar可对先前患过心梗的糖尿病患者起到有效的二级预防作用

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

Mejor Respuesta al Clopidogrel a Mayores Niveles de Tabaquismo

Better Clopidogrel Response Seen with Increased Smoking Levels

Prasugrel Inhibits Platelet Function Better Than High-Dose Clopidogrel in Diabetics

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content